Presence of myositis specific autoantibodies including anti synthetase antibodies predict favorable outcomes to rituximab in patients with idiopathic inflammatory myositis: Retrospective observational study

Basit Öğe Kaydı
dc.contributor.authorOğuz, Eyüp
dc.contributor.authorKoca, Nevzat
dc.contributor.authorBektaş, Murat
dc.date.accessioned2025-08-15T07:37:50Z
dc.date.available2025-08-15T07:37:50Z
dc.date.issued2025
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Romatoloji Ana Bilim Dalı
dc.description.abstractBackground: Idiopathic inflammatory myositis (IIM) is a group of disorders that mainly affect skeletal muscle, joints, skin, and lungs. Objectives: This study aimed to evaluate the autoantibody profile including myositis-associated autoantibodies (MAAs) and myositis-specific autoantibodies (MSAs) and their influence on outcomes, response rates, and associated factors to Rituximab (RTX) treatment in patients with IIM who followed up in a single tertiary center. Methods: Data from the patients with IIM who follow-up between 2019 and 2023 years and met the Bohan and Peter and/or the ACR/EULAR 2017 and/or the ENMC criteria were retrospectively reviewed. RTX was initiated in patients who had an inadequate response to at least one immonomudulatory/immunosuppressive treatment (refractory group) or as a first-line treatment in patients who had critical/severe disease manifestations such as respiratory failure due to severe intertitial lung disease (ILD), respiratory muscle involvement, and dysphagia. RTX was administered at a dose of 1 g every 6 months on days 0-15, and the dose was repeated at month 6 in patients who responded to treatment. Remission was defined as the patients who met all of the following criteria during at least 6 months: i) absence of a sign of muscle inflammation by manual muscle test (normalization of muscle strength in patients without damage) alongside muscle enzymes (normalization in CK and LDH levels), ii) improvement or no progression in respiratory symptoms alongside pulmonary function tests (less than 10% decline in FVC and/or DLCO) in patients who had ILD at baseline, iii) disappearance of active skin lesions among dermatomyositis (DM) patients iv) resolution of other features attributed to several manifestations such as arthritis, heart involvement and gastrointestinal symptoms if present.
dc.identifier.citationOğuz, E., Koca, N., & Bektaş, M. (2025). Presence of myositis specific autoantibodies including anti synthetase antibodies predict favorable outcomes to rituximab in patients with idiopathic inflammatory myositis: Retrospective observational study. Annals of the Rheumatic Diseases, 84, pp. 1680-1681. https://doi.org/10.1016/j.ard.2025.06.1112
dc.identifier.doi10.1016/j.ard.2025.06.1112
dc.identifier.endpage1681
dc.identifier.issn0003-4967
dc.identifier.issn1468-2060
dc.identifier.scopusqualityQ1
dc.identifier.startpage1680
dc.identifier.urihttps://doi.org/10.1016/j.ard.2025.06.1112
dc.identifier.urihttps://hdl.handle.net/20.500.13055/1069
dc.identifier.volume84
dc.identifier.wosWOS:001530469900001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expanded
dc.institutionauthorBektaş, Murat
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofAnnals of the Rheumatic Diseases
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectRemission
dc.subjectObservational Studies/Registry
dc.subjectAutoantibodies
dc.subjectReal-World Evidence
dc.subjectBiological DMARD
dc.titlePresence of myositis specific autoantibodies including anti synthetase antibodies predict favorable outcomes to rituximab in patients with idiopathic inflammatory myositis: Retrospective observational study
dc.typeConference Object
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
Tam Metin / Full Text
Boyut:
4.08 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu